Class 9 Biology Chapter 10: Biotechnology and its Applications – Complete Important Questions & Solutions

Biotechnology is one of the three core chapters in Class 9 Biology (alongside Heredity and Improvement in Food Resources). The CBSE board regularly tests conceptual depth: not just 'what is a GM crop,' but 'why are GM crops needed,' 'how are transgenic animals created,' and 'how does gene therapy treat disease.' The rationalized syllabus has reduced some examples, but the core definitions and applications remain non-negotiable. Examiners favour case-based scenarios (e.g., 'Bt cotton reduces pesticide use—explain how') and comparative questions (GM vs. conventional crops). Scoring full marks on Chapter 10 requires: (1) precise terminology, (2) understanding of the recombinant DNA process, (3) real-world examples (Bt cotton, Golden Rice, insulin-producing bacteria), and (4) ethical awareness. These 18 questions are structured across mark bands—1-mark recall, 2-mark short explanations, 3-mark process descriptions, and 5-mark critical analysis—to match the exact board question distribution. Practising these patterns builds both speed and accuracy.

**Q1: Which of the following is a genetically modified crop widely grown in India?** A) Wheat (traditional) B) Bt cotton C) Sugarcane (conventional) D) Rice (non-basmati) **Answer: B) Bt cotton** Bt cotton contains a gene from *Bacillus thuringiensis* bacterium, making it resistant to cotton bollworm. It was first approved for cultivation in India in 2002 and is now grown in ≈95% of Indian cotton fields. **Q2: Gene therapy is used to:** A) Increase crop yield permanently B) Replace defective genes with normal copies C) Create new species D) Produce vaccines only **Answer: B) Replace defective genes with normal copies** Gene therapy corrects genetic disorders by inserting a functional gene into a patient's cells. Example: treating adenosine deaminase (ADA) deficiency in humans. **Q3: Transgenic animals are produced by:** A) Selective breeding alone B) Introducing foreign DNA into the genome C) Mutation only D) Cross-breeding different species **Answer: B) Introducing foreign DNA into the genome** Transgenic animals carry deliberately inserted genes from other organisms. Example: insulin-producing goats have the human insulin gene inserted into their genome. **Q4: Golden Rice is enriched with:** A) Iron only B) Vitamin C C) β-carotene (vitamin A precursor) D) Calcium **Answer: C) β-carotene (vitamin A precursor)** Golden Rice was developed to address vitamin A deficiency in Asia. The yellow colour comes from accumulated β-carotene, which the body converts to vitamin A. **Q5: Bt stands for:** A) Biotechnology B) *Bacillus thuringiensis* C) Biological trait D) Better toxin **Answer: B) *Bacillus thuringiensis*** *Bacillus thuringiensis* is a soil bacterium that produces a protein (Bt toxin) lethal to insect larvae, making it ideal for developing insect-resistant crops.

**Q1: Explain how Bt cotton is produced. What pest does it protect against?** **Answer:** Bt cotton is produced by introducing the *crygene* (Bt toxin gene) from *Bacillus thuringiensis* into the cotton plant genome using recombinant DNA technology. The resulting plant produces Bt toxin in its cells, which is lethal to cotton bollworm (Helicoverpa armigera) larvae. When the larva ingests the plant tissue, the toxin disrupts its digestive system, killing it without harming humans or non-target organisms. **Q2: What is the difference between a GM crop and a transgenic animal?** **Answer:** A GM crop is a plant whose genome has been altered to introduce desirable traits (e.g., pesticide resistance, disease resistance, or nutritional enhancement). A transgenic animal is an animal that carries foreign genes from another organism in every cell of its body, usually to produce medically useful proteins or exhibit modified traits. Example: Bt cotton (GM crop) vs. insulin-producing goats (transgenic animal). **Q3: Name two advantages of GM crops over conventional crops.** **Answer:** (1) **Reduced pesticide use:** Bt crops produce their own insecticide, reducing chemical spraying and lowering environmental contamination and farmer exposure. (2) **Improved nutrition:** Golden Rice produces β-carotene, addressing vitamin A deficiency in developing countries. Alternative answers: increased yield, drought resistance, herbicide tolerance. **Q4: What is gene therapy? Give one example.** **Answer:** Gene therapy is the insertion of a normal, functional gene into a patient's body to replace a defective gene and cure genetic disorders. **Example:** Adenosine deaminase (ADA) deficiency—a severe immunodeficiency. A normal ADA gene is inserted into the patient's lymphocytes (T-cells), restoring enzyme production and immune function. Alternative examples: cystic fibrosis, sickle-cell anemia (potential future therapy). **Q5: How are transgenic animals created? Give one application.** **Answer:** Transgenic animals are created by microinjecting foreign DNA (the desired gene) directly into the nucleus of a fertilized egg. The egg is then implanted into a surrogate mother. Offspring that carry the foreign gene in all their cells are transgenic. **Application:** Insulin-producing goats—the human insulin gene is inserted so the goat's milk contains human insulin, which is extracted and used to treat diabetic patients. This is cheaper and more sustainable than chemical synthesis.

**Q1: Describe the process of producing a genetically modified crop using recombinant DNA technology.** **Answer:** 1. **Identify the trait:** Scientists identify a desirable gene (e.g., insect resistance from *Bacillus thuringiensis*). 2. **Extract and isolate:** The gene is isolated from the source organism using restriction enzymes (molecular scissors). 3. **Create recombinant DNA:** The isolated gene is inserted into a plasmid (small circular DNA) from a bacterium using DNA ligase (molecular glue), creating recombinant DNA. 4. **Introduce into plant cells:** The recombinant plasmid is introduced into crop plant cells (e.g., cotton) using a bacterium (*Agrobacterium tumefaciens*) as a vector or through gene gun method. 5. **Selection & screening:** Transformed cells are identified using marker genes and grown into complete plants. 6. **Testing:** GM plants are tested for trait expression and safety before release. **Example:** Bt cotton carries the *crygene*, producing Bt toxin that kills insect pests. **Q2: Explain why gene therapy offers hope for incurable genetic diseases.** **Answer:** Genetic diseases arise from defective genes that produce non-functional or harmful proteins, leading to illness. Traditional medicines cannot address the root cause—the defective gene itself. Gene therapy works by: (1) **Replacing the faulty gene** with a normal copy, restoring proper protein function and disease symptoms; (2) **Repairing the mutation** at the DNA level, offering long-term or permanent cure rather than symptom management; (3) **Targeting specific tissues** where the disease originates, minimizing side effects. For example, in ADA deficiency, the immune system fails because lymphocytes lack the enzyme adenosine deaminase. Inserting the normal ADA gene restores enzyme production, allowing immune cells to function. This approach works for single-gene disorders like cystic fibrosis, haemophilia, and sickle-cell anaemia, offering potential cures where no treatment previously existed. **Q3: Compare the advantages and disadvantages of growing GM crops.** **Answer:** **Advantages:** - Reduced pesticide use (e.g., Bt cotton reduces insecticide spraying by ≈60%). - Improved crop yield and stability. - Enhanced nutrition (e.g., Golden Rice with β-carotene addresses micronutrient deficiency). - Resistance to drought, flooding, or disease. **Disadvantages:** - **Environmental concerns:** Gene flow to wild relatives or non-GM crops; potential impact on non-target organisms; soil microbiome disruption. - **Health concerns (unproven but debated):** Long-term safety data in humans remains limited; allergenicity potential. - **Socioeconomic issues:** High seed cost; dependency on seed companies; reduced crop diversity. - **Regulatory challenges:** Different countries have varying approval standards, limiting global trade. **Q4: How are transgenic animals useful in medicine? Explain with two examples.** **Answer:** Transgenic animals are genetically modified to produce medically important proteins in their milk, blood, or tissues, making them "biofactories" for drug production. **Example 1 – Insulin-producing goats:** The human insulin gene is inserted into goats' genomes. The protein is expressed in mammary glands and secreted in milk. Insulin is then extracted and purified for treating diabetes mellitus. This is cost-effective and sustainable compared to chemical synthesis. **Example 2 – Clotting factor-producing sheep:** Sheep are engineered to produce human clotting factor (e.g., Factor VIII or IX) in their milk. Patients with haemophilia (blood clotting disorder) receive these factors extracted from sheep milk, preventing life-threatening bleeding. Production in milk is more efficient and affordable than bioreactor fermentation. **Medical benefits:** (1) Reduced pharmaceutical production costs; (2) safer product (no contamination from other pathogens); (3) renewable supply; (4) faster protein production scaling.

**Q1: Explain how Bt cotton benefits farmers and the environment. Discuss any potential risks associated with its long-term cultivation.** **Answer:** **Benefits to Farmers:** 1. **Reduced pesticide cost:** Bt cotton produces its own insecticide (Bt toxin) in its tissues. When cotton bollworm larvae feed on the plant, the toxin destroys their gut lining, causing death. This eliminates the need for ≈5–8 pesticide sprays per season, reducing input cost by 30–50% and saving ₹5,000–10,000 per hectare. 2. **Higher yield:** Lower pest damage means more mature bolls and higher cotton yield per plant. Indian farmers have reported 20–30% yield increase since Bt cotton's introduction in 2002. 3. **Safety:** Reduced chemical exposure decreases health risks for farmers and farm workers (e.g., pesticide poisoning, skin allergies). 4. **Time savings:** Fewer spraying activities mean more time for other farm work or rest. **Environmental Benefits:** 1. **Reduced chemical runoff:** Lower pesticide use reduces soil and water pollution. Chemical pesticides often kill non-target insects (bees, butterflies) and contaminate groundwater; Bt toxin is soil-degradable and non-toxic to vertebrates. 2. **Biodiversity:** Fewer sprays preserve beneficial insects, birds, and soil microorganisms essential for ecosystem health. 3. **Sustainability:** Lower chemical dependency reduces agriculture's environmental footprint. **Potential Risks & Concerns:** 1. **Pest resistance:** Excessive or continuous use of Bt cotton may select for Bt-resistant pests. If bollworm population is exposed to Bt toxin continuously without non-Bt crop refugia, resistance mutations accumulate, rendering the technology ineffective within 5–10 years. **Mitigation:** Farmers are recommended to plant 5–10% non-Bt cotton (refuge) to maintain susceptible pest populations. 2. **Gene flow:** Bt genes may spread to wild cotton relatives or conventional cotton via pollen, creating uncontrolled GM populations in nature. 3. **Soil impact:** Long-term Bt toxin accumulation in soil may affect microbial communities, though evidence is limited. 4. **Dependency:** Farmers become dependent on expensive Bt seeds from corporations, potentially increasing debt. 5. **Socioeconomic:** Widespread adoption reduces crop diversity, risking food security if a new pest emerges. **Conclusion:** Bt cotton has delivered substantial benefits over two decades, but sustainable cultivation requires integrated pest management (IPM) practices—rotating crops, maintaining refugia, and monitoring resistance emergence. --- **Q2: Describe the principle and process of gene therapy. Why is it considered a breakthrough for treating genetic disorders?** **Answer:** **Principle:** Gene therapy operates on the principle that genetic diseases originate from defective or mutated genes that produce non-functional proteins. By introducing a normal, functional copy of the gene into the patient's cells, the defective gene's effects can be corrected, restoring normal protein function and curing the disease at its root cause—unlike conventional medicine, which only manages symptoms. **Process of Gene Therapy:** 1. **Diagnosis:** Identify the genetic defect and the specific gene mutation causing the disease (e.g., adenosine deaminase deficiency in ADA-SCID). 2. **Gene isolation:** Obtain a normal, functional copy of the defective gene from a healthy donor or synthesize it in the laboratory. 3. **Vector preparation:** Insert the normal gene into a vector—a carrier molecule that can deliver the gene into patient cells. Common vectors include: - **Viral vectors:** Harmless viruses (e.g., adenovirus, retrovirus) engineered to carry the gene and infect target cells. - **Non-viral vectors:** Direct injection or electroporation (electrical pulses) to introduce DNA into cells. 4. **Delivery to patient cells:** Introduce the vector containing the normal gene into the patient's body. For somatic gene therapy (affecting only body cells, not germ cells), target cells may be extracted, treated in vitro (in the lab), and reintroduced. Example: In ADA deficiency, T-lymphocytes are extracted from the patient's blood, treated with the normal ADA gene, and returned to the patient's body. 5. **Gene integration:** The normal gene integrates into the patient's cell chromosome, becoming a permanent part of the genome (or remains episomal, functioning independently). 6. **Protein expression:** The integrated gene is transcribed into mRNA and translated into functional protein, restoring normal cellular function. 7. **Monitoring:** Track patient recovery, protein levels, and any adverse effects over time. **Why Gene Therapy Is a Breakthrough:** 1. **Root-cause treatment:** Unlike drugs that manage symptoms, gene therapy addresses the genetic defect itself, offering potential permanent cure rather than lifelong medication. 2. **Single-gene disorder success:** Highly effective for monogenic (single-gene) diseases like: - **ADA-SCID (Adenosine Deaminase Severe Combined Immunodeficiency):** First disease treated with gene therapy (1990). Patients' immune systems were restored, allowing normal life expectancy. - **Haemophilia:** Gene therapy can produce clotting factors, eliminating bleeding episodes. - **Cystic fibrosis:** In development; restoring CFTR gene function in lung cells. - **Sickle-cell anaemia:** Emerging therapy showing promise in recent trials. 3. **Reduced dependency on drugs:** Patients avoid lifelong medication (e.g., insulin injections, blood transfusions), improving quality of life and reducing healthcare costs. 4. **Personalized medicine:** Gene therapy can be tailored to each patient's specific mutation, offering precise treatment. 5. **Prevention potential:** Germline gene therapy (modifying eggs, sperm, or early embryos—ethically debated) could prevent genetic diseases from passing to future generations. **Limitations & Ethical Concerns:** - High cost (₹1–10 crores per treatment). - Off-target effects (gene integration at unintended sites causing harm). - Germline modification raises ethical concerns about "designer babies" and equity. - Long-term safety data in humans is still accumulating. **Conclusion:** Gene therapy represents a paradigm shift from symptomatic treatment to causal treatment, offering hope for previously incurable genetic disorders. While challenges remain, recent FDA approvals demonstrate its clinical viability. --- **Q3: Golden Rice is described as a 'GM crop for social good.' Explain its genetic modification, nutritional benefit, and current adoption challenges.** **Answer:** **Genetic Modification of Golden Rice:** Golden Rice was developed to address vitamin A deficiency (VAD), the leading cause of preventable blindness in children in Asia and Africa. Traditional rice lacks β-carotene (vitamin A precursor). Researchers introduced three genes into rice: 1. **psy gene** (phytoene synthase) from daffodil: Initiates β-carotene synthesis. 2. **crt I gene** (phytoene desaturase) from a bacterium (*Erwinia uredovora*): Continues the synthesis pathway. 3. **lcy gene** (lycopene cyclase) from maize: Completes the pathway to form β-carotene. These genes were stacked into the rice genome using Agrobacterium-mediated transformation. The rice endosperm (the edible part) now accumulates β-carotene, giving it a yellow or "golden" colour. One cup of cooked Golden Rice provides ≈50% of the daily vitamin A requirement for children. **Nutritional Benefits:** 1. **Vitamin A deficiency prevention:** VAD affects ≈250 million children globally, causing: - Xerophthalmia (dry eyes, leading to blindness). - Weakened immunity, increasing infection risk. - Poor growth and development. Golden Rice provides a staple-based vitamin A source, particularly valuable in rice-eating populations (Asia, parts of Africa). 2. **Cost-effective intervention:** Unlike supplementation programs requiring distribution, Golden Rice integrates vitamin A delivery into the food supply chain, reaching poor populations who may lack access to fortified foods or supplements. 3. **Culturally acceptable:** Rice is a staple; no change in eating habits required. 4. **Bioavailability:** β-carotene from rice is better absorbed when consumed with fat, which is typical in traditional rice dishes. **Adoption Challenges:** 1. **Low initial acceptance:** Farmers and consumers in Asia were skeptical of "unnatural" GM rice. Social resistance required extensive public education campaigns. 2. **Low β-carotene content in early versions:** The first generation of Golden Rice (GR1, 2000) had low β-carotene levels (≈1.6 μg/g). A newer version (GR2, 2005) increased this to ≈10 μg/g, but even this requires eating ≈200g rice daily to meet vitamin A needs—unrealistic for poor populations. Newer variants (e.g., GR3) aim for higher levels. 3. **Regulatory delays:** Different countries imposed strict approval requirements. Bangladesh approved GR2 in 2021 (after 20+ years of development), and India still has not officially approved it for cultivation (as of 2024), citing preference for diversified food systems and fortification programs. 4. **Existing alternatives:** Fortification (adding vitamin A to rice during milling), dietary diversification (leafy greens, carrots, animal products), and supplementation programs are proven, cheaper, and faster. India's Public Distribution System already distributes fortified rice. 5. **Distribution infrastructure:** In poor countries, the gap between development and farmer adoption is large. Golden Rice requires the same cold-chain and distribution systems as any crop, which is often inadequate in rural areas. 6. **Cost:** Golden Rice seeds are more expensive than conventional varieties, discouraging adoption among subsistence farmers. 7. **IPR & access issues:** Patent restrictions limit access in developing countries; free licensing agreements exist but vary by region. **Current Status & Future:** - Bangladesh approved GR2 in 2021 and began limited cultivation in 2023. - Philippines approved it in 2021; cultivation started in 2022. - India prefers fortification and food-based approaches; no official approval yet. - Newer varieties (GR3 and beyond) aim for higher β-carotene content and better agronomic traits. **Conclusion:** While Golden Rice symbolizes the potential of GM crops for humanitarian goals, its limited adoption highlights that biotechnology alone cannot solve complex problems rooted in poverty, infrastructure, and policy. It works best as part of a multi-pronged strategy including fortification, supplementation, and dietary diversification.

**Case Study: Treating ADA-SCID with Gene Therapy** Adenosine deaminase (ADA) deficiency causes Severe Combined Immunodeficiency (ADA-SCID), a fatal genetic disorder where patients cannot fight infections because their T-lymphocytes (immune cells) lack the enzyme adenosine deaminase. In 1990, a 4-year-old girl with ADA-SCID became the first human to receive gene therapy. T-cells were extracted from her blood, treated with the normal ADA gene using a retroviral vector, and reintroduced into her body. Over months, her immune system recovered, and she lived a relatively normal life. **Questions:** 1. **Why were T-lymphocytes chosen as the target cells rather than attempting to modify liver or bone marrow cells directly in the patient's body?** **Answer:** T-lymphocytes were extracted and treated ex vivo (outside the body) for several reasons: (a) **Safety:** Modifications can be verified in the lab before reintroduction, reducing off-target effects; (b) **Efficiency:** Retroviruses integrate specifically into dividing cells, and T-cells are readily cultured and expanded; (c) **Monitoring:** Treated cells can be screened for successful gene integration before return; (d) **Ethical control:** Somatic gene therapy (affecting only the treated cells, not germ cells) is less controversial than germline modification; (e) **Direct benefit:** The defective cells themselves are treated, directly restoring immune function without waiting for new cell production from bone marrow. 2. **Explain how the retroviral vector delivered the ADA gene into T-cells, and why retroviruses are suitable vectors.** **Answer:** The retroviral vector is an engineered virus with the normal ADA gene inserted in place of viral genes needed for replication (making it non-infectious). It works by: (1) **Binding:** The viral envelope proteins bind to receptors on the T-cell surface; (2) **Entry:** The virus fuses with the cell membrane, injecting its RNA genome carrying the ADA gene; (3) **Reverse transcription:** Retroviral reverse transcriptase converts the RNA into DNA (cDNA); (4) **Integration:** The viral integrase enzyme inserts the cDNA (including the ADA gene) into the T-cell's chromosome; (5) **Expression:** The integrated ADA gene is transcribed and translated, producing functional ADA enzyme. Retroviruses are suitable because: (a) They naturally integrate into the host genome, providing stable, permanent gene expression; (b) They efficiently infect T-lymphocytes; (c) They can carry genes up to ≈8 kb in size; (d) Low immunogenicity (don't trigger strong immune rejection). 3. **Why did the patient's immunity improve even though the treated T-cells represent only a fraction of her total immune cell population?** **Answer:** Although the initial infusion of gene-modified T-cells was limited, several factors enabled immune recovery: (1) **T-cell proliferation:** Modified T-cells with functional ADA multiplied in the patient's body through normal immune responses. Over months, they expanded to constitute a significant portion of circulating T-cells; (2) **Restored thymus function:** With functional T-cells providing feedback, the thymus gland (which produces T-cells) resumed activity and produced new T-cells naturally; (3) **Network effect:** Even a small percentage of functional T-cells can coordinate immune responses, activating B-cells and other immune components; (4) **Long-term persistence:** Retrovirally modified T-cells integrate the ADA gene into their DNA, so every daughter cell produced by division carries the corrected gene, providing long-term benefit. 4. **Discuss one advantage and one limitation of this ex vivo (in-laboratory) gene therapy approach.** **Answer:** **Advantage:** **Precise control and safety.** Cells are treated in the lab, allowing researchers to verify successful gene integration, screen for unwanted mutations, and confirm ADA enzyme production before reintroduction. This reduces the risk of off-target effects or unintended consequences compared to in vivo (in-body) gene delivery. **Limitation:** **Repeated infusions required.** Retroviral vectors integrate only into dividing cells. Over time, treated T-cells die naturally (lifespan ≈10 years for some T-cells), requiring periodic re-infusion of newly treated cells. This demands repeated procedures, is costly, and increases infection risk each time. Additionally, treated cells may not fully replicate the body's natural thymic production of diverse T-cells, leaving some immune gaps. Modern therapies attempt to target bone marrow stem cells to achieve permanent cure, but stem cell targeting in vivo is technically challenging. **Learning Outcome:** This case illustrates both the power of gene therapy (first human cure) and the gap between laboratory success and lifelong clinical outcomes.

Understanding Biotechnology requires moving beyond rote memorization to grasp process-based learning—how recombinant DNA is created, how vectors deliver genes, why Bt cotton works, and how gene therapy offers hope. CBSETUTOR.ai's AI tutor personalizes this journey for each Class 9 student. **Daily Micro-Drills:** Every session targets weak areas. If you struggle with gene therapy timelines, the AI generates scenario-based questions (e.g., "Patient A receives gene therapy on Day 1. By Day 90, her T-cell count is normal. Explain what happened in her bone marrow"). Questions regenerate infinitely, ensuring no memorization of answer keys—true learning. **Board-Pattern Sequencing:** Questions are ordered by difficulty and mark-value. Warm up with 1-mark MCQs, progress to 2-mark definitions, then tackle 3-mark process explanations, and finally synthesize 5-mark critical essays. This mirrors actual board exams, building exam-day confidence. **Auto-Grading with Step-Wise Feedback:** After you answer, the AI reveals not just 'correct/incorrect,' but *where* your reasoning broke down. Example: If you wrote 'Bt cotton kills pests by producing insecticide in its leaves,' the AI acknowledges the core idea but clarifies: 'Correct—but specify which insects (bollworm), which protein (Bt toxin), and the mechanism (gut lining rupture).' This gap-filling accelerates learning. **Adaptive Spaced Repetition:** Questions you've mastered appear less frequently; those you struggle with resurface at optimal intervals (2 days, 1 week, 2 weeks) with slight variations, cementing long-term retention. Perfect for preparing over 6–8 weeks before boards. **Real-Time Cross-Linking:** When answering a Chapter 10 question, if you misunderstand the DNA structure, the AI offers a 30-second refresher on Chapter 5 (Cell Structure) before continuing. No gaps in foundational knowledge. **Mock Exam Mode:** Simulate a 2-hour internal assessment or board exam. Answer 12–15 Chapter 10 questions under timed conditions (exactly as in school). Instant result, question-by-question breakdown, and a personalized revision plan for weak topics. **Start a 3-day free trial at cbsetutor.ai** to experience how daily AI-powered drills transform 'I know it' into 'I can answer it under exam pressure.'